Keski Hakan, Merdan Selim, Zemheri Itır Ebru
University of Health Sciences Türkiye, Ümraniye Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye
University of Health Sciences Türkiye, Ümraniye Training and Research Hospital, Clinic of Microbiology, İstanbul, Türkiye
Turk J Haematol. 2024 Dec 2;41(4):236-245. doi: 10.4274/tjh.galenos.2024.2024.0149. Epub 2024 Oct 8.
Despite advancements in treatment, multiple myeloma (MM) remains a challenging hematologic malignancy. It is crucial to stratify risk and perform prognostic assessment with various markers, including the expression of cluster of differentiation 56 (CD56) and cluster of differentiation 117 (CD117). However, the relationship of these markers with MM-related survival remains unclear. In this context, the objective of this study was to investigate the prognostic implications of CD56 and CD117 expression and associated clinical features in MM patients.
The population of this retrospective single-center study consisted of adult MM patients whose CD56 and CD117 expression levels were analyzed. Patients were divided into four groups according to their immunophenotypes: CD56CD117, CD56CD117, CD56CD117, and CD56CD117. These groups were compared in terms of demographic and clinical characteristics, response to treatment, and survival outcomes.
Of the 168 MM patients included in the study, CD56 positivity, CD117 positivity, CD56 and CD117 double positivity, and CD56 and CD117 double negativity were observed in 57.1%, 38.1%, 21.4%, and 26.2%, respectively. Patients with double positivity had significantly higher cytogenetic risk and significantly lower overall response rate (ORR) compared to other patients (p<0.001 for both). ORR and overall survival (OS) were significantly lower in CD56-positive patients than in CD56-negative patients (p=0.017 and p=0.004, respectively). Mortality rates were significantly higher in CD56-positive and CD117-positive patients than in double-negative patients (p<0.001 and p=0.002, respectively). Double-negative patients had significantly lower ORR and OS and higher mortality than others (p=0.001, p=0.002, and p<0.001, respectively). High cytogenetic risk was found to be an independent predictor of shorter OS (p>0.001).
This study’s findings revealed that MM patients with CD56 and CD117 double positivity had poorer prognosis, lower ORR, shorter OS, and higher mortality.
尽管治疗取得了进展，但多发性骨髓瘤（MM）仍然是一种具有挑战性的血液系统恶性肿瘤。使用包括分化簇56（CD56）和分化簇117（CD117）表达在内的各种标志物进行风险分层和预后评估至关重要。然而，这些标志物与MM相关生存的关系仍不清楚。在此背景下，本研究的目的是探讨CD56和CD117表达及相关临床特征对MM患者的预后影响。
这项回顾性单中心研究的人群包括分析了CD56和CD117表达水平的成年MM患者。根据免疫表型将患者分为四组：CD56⁺CD117⁺、CD56⁺CD117⁻、CD56⁻CD117⁺和CD56⁻CD117⁻。对这些组在人口统计学和临床特征、治疗反应及生存结果方面进行比较。
在纳入研究的168例MM患者中，CD56阳性、CD117阳性、CD56和CD117双阳性以及CD56和CD117双阴性的比例分别为57.1%、38.1%、21.4%和26.2%。与其他患者相比，双阳性患者的细胞遗传学风险显著更高，总缓解率（ORR）显著更低（两者p均<0.001）。CD56阳性患者的ORR和总生存期（OS）显著低于CD56阴性患者（分别为p = 0.017和p = 0.004）。CD56阳性和CD117阳性患者的死亡率显著高于双阴性患者（分别为p<0.001和p = 0.002）。双阴性患者的ORR和OS显著更低，死亡率高于其他患者（分别为p = 0.001、p = 0.002和p<0.001）。高细胞遗传学风险被发现是OS较短的独立预测因素（p>0.001）。
本研究结果显示，CD56和CD117双阳性的MM患者预后较差，ORR较低，OS较短，死亡率较高。
